Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2007

View Archived Issues

Animal models of colitis reveal potential of NU-206 treatment

Novel Alzheimer's vaccine candidate developed at UBI

Recent patents disclose novel therapeutic agents for respiratory and allergic disorders

Nonhematotoxic naphthalimide derivative and prodrug show promising preclinical activity

Schering-Plough selects collaborative compound for preclinical development

Recent Pfizer patent claims novel therapeutic agents for thrombocytopenia

Avexa and TargetDrug formalize CCR5 HIV drug program collaboration

Genta plans new phase III study of Genasense in advanced melanoma

Vasogen and Ferrer collaborate to commercialize Celacade in E.U., Latin America

New phase II trial studies anti-IgE immunotherapy RP-01

De Novo designs novel inhibitors for 11beta-hydroxysteroid dehydrogenase

Shire completes tender offer for New River shares

Indevus seeks to return Valstar to U.S. market

Novacea gains additional rights to AQ4N

European orphan drug designation for PDX in peripheral T-cell lymphoma

Access and Somanta sign definitive merger agreement

First phase II study under way for cetrorelix for BPH

Vaxfectin to be studied for use in malaria under new agreement

Merck KGaA and WHO conclude partnership for schistosomiasis in Africa

Japanese phase I trial completed for antiinfluenza drug CS-8958

E-2007 studied to lengthen effectiveness of L-dopa treatment in Parkinson's

Keppra effective as adjunctive therapy in partial onset seizures in young children

Anturol absorbed on bioequivalent basis from three application sites

NDA filing for fixed-dose Niaspan/simvastatin tablet

BGC-945 emerges as a tumor-targeted agent with minimal toxicity

Full FDA approval for DepoCyt for lymphomatous meningitis

MAb targeting DR5 induces apoptosis and tumor regression without toxicity

Potent and selective c-Met inhibitor described at AACR by Merck team